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Abstract
The gut microbiota has been implicated in obesity and its progression towards metabolic disease. Dietary interventions that target the gut
microbiota have been suggested to improve metabolic health. The aim of the present study was to investigate the effect of interventions
with Lactobacillus paracasei F19 or flaxseed mucilage on the gut microbiota and metabolic risk markers in obesity. A total of fifty-eight
obese postmenopausal women were randomised to a single-blinded, parallel-group intervention of 6-week duration, with a daily
intake of either L. paracasei F19 (9·4 £ 1010 colony-forming units), flaxseed mucilage (10 g) or placebo. Quantitative metagenomic analysis
of faecal DNA was performed to identify the changes in the gut microbiota. Diet-induced changes in metabolic markers were explored
using adjusted linear regression models. The intake of flaxseed mucilage over 6 weeks led to a reduction in serum C-peptide and insulin
release during an oral glucose tolerance test (P,0·05) and improved insulin sensitivity measured by Matsuda index (P,0·05). Comparison
of gut microbiota composition at baseline and after 6 weeks of intervention with flaxseed mucilage showed alterations in abundance of
thirty-three metagenomic species (P,0·01), including decreased relative abundance of eight Faecalibacterium species. These changes in
the microbiota could not explain the effect of flaxseed mucilage on insulin sensitivity. The intake of L. paracasei F19 did not modulate
metabolic markers compared with placebo. In conclusion, flaxseed mucilage improves insulin sensitivity and alters the gut microbiota;
however, the improvement in insulin sensitivity was not mediated by the observed changes in relative abundance of bacterial species.
Key words: Gut microbiota: Probiotics: Flaxseed mucilage: Obesity-related disease: Metagenomics
More than half a billion people are obese worldwide, causing an
estimated 2·8 million deaths each year due to metabolic
comorbidities, such as CVD and type 2 diabetes (T2D)(1). Meta-
genomic studies have suggested that obesity-related metabolic
diseases are accompanied by alterations in gut bacteria gene
composition and abundance(2–7). Noticeably, microbial genes
seem to be a stronger predictor of T2D than common anthro-
pometric risk markers(7) and variation in the human
genome(3), as shown in European and Chinese individuals,
respectively, although the most discriminatory microbial genes
differed between the Chinese(3) and European individuals(7).
Still, it is not clear whether shifts in the gut microbiota can
cause metabolic diseases, or if they are just a consequence.
However, causality is suggested by studies in germ-free
mice(8,9), and one study in human subjects(10). These studies
have shown that transplantation of gut microbiota can
induce modifications in the microbiota of the receiving host,
associated with either impaired or improved metabolic
health, depending on the phenotype of the donor. Studies in
human subjects that have measured diet-induced alterations
in gut metagenomic and whole-body metabolic markers sim-
ultaneously have shown that modifications in the microbiota
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are accompanied by improvements in glucose homeostasis
and lipid metabolism(11,12). Together, these studies suggest
that the gut microbiota constitute a promising target in the pre-
vention of metabolic diseases.
Food components that directly target the gut microbiota
include pre- and probiotics. Probiotics are living micro-
organisms that, when ingested, provide health benefits,
either directly through interactions with host cells or indirectly
through effects on other bacterial species(13). Common pro-
biotics include Lactobacillus species(14), and Lactobacillus
paracasei has previously been associated with a healthy
metabolic profile(15,16). Prebiotics are dietary fibres that are
selectively fermented by the gut bacteria and induce specific
changes in the composition and/or activity of the gut micro-
biota that provide benefits to host health(17). Flaxseed
(Linum usitatissimum L.) contains approximately 30 % of
dietary fibres, of which one-third are soluble viscous fibres
(mucilage)(18) that induce beneficial effects on glucose
homeostasis and lipid metabolism in human subjects(19–21).
Flaxseed fibres have been shown to be highly fermentable
in rats(22); however, it is not known whether beneficial meta-
bolic effects of flaxseed mucilage on human subjects can be
explained by modulation of the gut microbiota.
The aim of the present study was to explore the effect of
dietary interventions either with L. paracasei F19 or with
flaxseed mucilage on gut microbiota and metabolic risk
markers in obese postmenopausal women.
Materials and methods
A total of fifty-eight women were randomised to a parallel-
group intervention of 6 weeks’ duration with a daily intake
of L. paracasei ssp. paracasei F19, flaxseed mucilage or pla-
cebo (Fig. 1). The participants were blinded to their allocation;
L. paracasei F19 was mixed with maltodextrin and adminis-
tered in sachets and the indistinguishable placebo product
was administered in sachets with a corresponding dose of
maltodextrin. Flaxseed mucilage was administered in break-
fast buns and the corresponding placebo products were
buns without flaxseed mucilage.
The primary outcomes were the effect on the gut
microbiota composition and insulin sensitivity; the secondary
outcomes were the effect on the inflammatory markers,
blood lipids and fat mass distribution. Enrolment of partici-
pants was performed continuously by the same two research-
ers, and randomisation was carried out continuously using
pre-prepared opaque sealed envelopes with an equal allo-
cation ratio of 1:1:1. Sample size calculations were based on
preliminary results from a subgroup of Danish participants
in the Metagenomics of the Human Intestinal Tract (MetaHIT)
study(5). With a sample size of eighteen participants per group,
a statistical power of 80 %, a two-sided significance level of
0·05 and with the assumption of equal variances, the study
will identify the changes between independent groups in gut
microbiota composition corresponding to 1 SD, e.g. a differ-
ence of 40 000 gene counts will be identified if the SD is
40 000 gene counts, and similarly, a 0·5 difference in insulin
sensitivity (homeostatic model assessment of insulin resist-
ance, HOMA-IR) will be identified for an SD of 0·5.
The participants attended a screening visit within the
2 weeks before randomisation and four visits after enrolment:
visit 1 at baseline (day 0); visit 2 at day 28 of the intervention;
visit 3 at the end of the intervention (day 42) and visit 4
4 weeks after the end of the intervention. After the completion
of the study, the participants were offered a 10-week weight
reduction programme. During the visits, blood was drawn,
faecal samples were collected, body composition and blood
pressure were measured, and information on dietary intake,
physical activity level and adverse events were obtained.
The present analyses included the 6-week intervention
period that was the primary outcome of the study.
Study population
Participants were recruited from the Copenhagen area through
advertisements in newspapers and relevant web sites. The
inclusion criteria were women aged 40–70 years,$1 year since
last menstruation, BMI of 30–45 kg/m2, waist circumference
.80 cm and leucocyte blood count .4·7 £ 109 cells/l. The
exclusion criteria were gastrointestinal diseases, chronic
diseases (such as type 1 diabetes or liver cirrhosis), medically
treated T2D or dyslipidaemia, intake of antibiotics within the
previous 3 months, intake of supplementary pro- or prebiotics
or abnormal high quantities of fermented foods (.400g/d)
in the previous 6 weeks, or inability to comply with the
research protocol. The present study took place at the Depart-
ment of Nutrition, Exercise and Sports, Faculty of Sciences,
University of Copenhagen, Denmark, from September 2011 to
September 2012.
The present study was conducted according to the guide-
lines laid down in the Declaration of Helsinki, and all
procedures involving human participants were approved by
the Ethics Committee for the Capital Region of Denmark
(journal H-3-2011-067). Written informed consent was
obtained from all participants. The present study was
registered at ClinicalTrial.gov (NCT01433120).
Baseline
(week 0)
(n 58)
End of
intervention
(week 6)
(n 53)
L. paracasei F19 mixed
with matodextrin+placebo buns
Flaxseed mucilage buns+maltodextrin
Placebo buns+maltodextrin
Fig. 1. Illustration of the 6-week parallel-group intervention, with participants randomised to one of the three different diet groups.
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Intervention
The probiotic product contained L. paracasei F19 (9·4 £ 1010
colony-forming units/dose). The probiotic and the placebo
(pure maltodextrin) sachets were indistinguishable. The
products were stored at 2808C until the weekly supply to
the participants, after which they were stored in their personal
freezer at 2188C until consumption. Participants dissolved the
entire content of the sachet in a glass of water and consumed
it in the morning. Bacterial viability was confirmed at the end
of the intervention by anaerobic culture tests of a sample of
the products. Dilution of samples was spread on deMan,
Rogosa and Sharpe (MRS) pH 5·4 agar. Plates were incubated
anaerobically 72 h at 378C. All characteristic colonies were
checked by microscopy and counted (Arla Foods amba).
Flaxseed mucilage was extracted from whole flaxseed
under heat treatment (Biogin Biochemicals Company Limited).
Breakfast buns based on wheat with and without flaxseed
mucilage were produced by the Department’s experimental
kitchen, and the daily amount of flaxseed mucilage adminis-
tered to the active group was 10 g (5 g/bun). The products
were stored at 2188C at the Department until the weekly
supply to the participants. The intervention and placebo
buns were comparable in visual appearance, taste and macro-
nutrient composition. They were consumed during the
morning hours. The participants were otherwise instructed
to maintain habitual dietary habits.
Participants were required to keep a diary of their intake of
study products, and these were collected at the weekly visits
at the Department. A compliance score was calculated as the
percentage of the prescribed test products a participant reported
to have consumed during the 6 weeks of intervention. The par-
ticipants were interviewed about all types of potential adverse
effects at each visit by the use of broad, open-ended questions;
in addition, they were asked specifically to changes in stool
characteristics (consistency and frequency).
Body composition, dietary and activity records
Body composition was assessed by dual-energy X-ray absorp-
tiometry (iDXA; Lunar Radiation Company), BMI (kg/m2),
waist circumference and intra-abdominal adipose tissue
(cm2: 2208·2 þ 4·62 (sagittal diameter, cm) þ 0·75 (age,
years) þ 1·73 (waist, cm) þ (0·78 (trunk fat, %)))(23).
Registration of 3 d weighed dietary intake and physical activity
level were performed within the week before each visit.
A registered dietitian analysed all dietary records using the
Danish dietary software program (Dankost Pro). Physical
activity was registered using the Physical Activity Scale(24)
where the metabolic equivalent value is calculated based on
the time spent on nine different intensity levels ranging from
sleep to very strenuous activities during 24 h.
Biochemical analyses
Fasting blood samples were obtained after an overnight
fast followed by an oral glucose tolerance test (OGTT)
where 75 g of glucose were dissolved in 300 ml of water and
consumed within 5 min. During the OGTT, blood samples
were taken with 30 min intervals for 3 h to ensure return to
baseline values. Blood for glucose analysis was collected in
iced sodium fluoride tubes. Blood samples for the analysis
of leucocytes count, high-sensitivity C-reactive protein
(hsCRP), lipopolysaccharide-binding protein (LBP), IL-6 and
angiopoietin-like protein 4 (ANGPTL4) were drawn in iced
EDTA tubes. Blood samples for all other analyses were
collected in non-coated tubes. Blood samples were
centrifuged for 10 min at 2500 g at 48C and kept at 2808C
until analyses were performed. Insulin resistance was assessed
by glucose, insulin and C-peptide at the fasting and stimulated
state. Inflammatory state was assessed by leucocytes count,
hsCRP, TNF-a, IL6 and LBP. Lipid metabolism was assessed
by measurement of serum concentrations of total cholesterol,
LDL-cholesterol, HDL-cholesterol and TAG, and plasma con-
centration of ANGPTL4. ABX Pentra 400 (Horiba ABX) was
used to analyse glucose (intra- and inter-assay CV: 1·1 and
1·5 %), TAG (intra- and inter-assay CV: 3·8 and 3·0 %), total
cholesterol (intra- and inter-assay CV: 1·0 and 1·7 %),
HDL-cholesterol (intra- and inter-assay CV: 1·2 and 2·7 %),
LDL-cholesterol (intra- and inter-assay CV: 1·3 and 3·3 %)
and hsCRP (intra- and inter-assay CV: 3·6 and 6·5 %). Immulite
1000 (Siemens Medical Solutions Diagnostics) was used to
analyse insulin (intra- and inter-assay CV: 4·2 and 7·3 %) and
C-peptide (intra- and inter-assay CV: 6·9 and 5·2 %). Sysmex
KX-21 hematology (Sysmex GmbH) was used to analyse the
leucocytes count (intra- and inter-assay CV: 2·0 and 1·4 %).
LBP (intra- and inter-assay CV: 6·1 and 9·8–17·8 %) was
analysed with a human LBP Elisa kit (Abnova). TNF-a (intra-
and inter-assay CV: 5·4 and 6·1 %), IL-6 (intra- and inter-assay
CV: 7·4 and 8·5 %) and ANGPTL4 (intra-assay CV: 3·8 %) were
analysed with ELISA (antibodies were purchased from R&D
Systems). Insulin resistance was estimated by HOMA-IR(25).
Data from the OGTT were evaluated by AUC analysis and
by the Matsuda index(26).
Stool samples and microbiota analyses
Participants collected samples of faeces in two 20 ml tubes
(samples A and B) within 2 d before the visit. The samples
were either stored immediately at 2808C or briefly stored in
personal 2188C freezers before transport to the laboratory
in cooled containers. Total faecal DNA from the fifty-three
participants who completed the dietary intervention was
extracted, sequenced and analysed by quantitative metage-
nomics at Metagenopolis (INRA). To obtain homogenous
representation of all bacterial species, DNA extraction
involved use of quenching solutions that protect DNA
potentially prematurely released by lysis of fragile cells from
degradation by DNases present in the stools and a bead-
beating step that assures lysis of particularly robust
cells(27,28). A Barcoded Fragment Library was prepared for
each sample and DNA sequencing data were generated
using the SOLiD 5500xl sequencers (Life Technologies). An
average of 65 (SD 48) million 50-base-long single reads was
determined for each sample.
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Primary data analyses, from reads to generation of a raw
count matrix, were performed using METEOR Studio pipeline
for quantitative metagenomic profiling developed at INRA
MetaGenoPolis based on the iMOMi database. Reads gener-
ated from the SOLiD sequencer were trimmed to thirty-five
bases and then mapped on the reference catalogue of 3·3
million genes(29) using Bowtie software with a maximum of
three mismatches and selection of the best hit. If multiple
alignments were found, counts were divided equally between
the aligned genes. Using both thirty-five bases reads and three
maximum mismatches allows to take into account the strain
variability and the non-redundant nature of the gene catalo-
gue where redundant open reading frames were removed
using a criterion of 95 % identity over 90 % of the shorter
open reading frame length. Average of 38 (SD 14) million
reads per sample was thus mapped and used to construct a
raw gene count matrix.
Secondary analyses, from matrix normalisation to micro-
biota analyses, were performed using MetaOMineR package,
an analytical suite (R language) developed at the INRA Meta-
GenoPolis(4,5) that contains different algorithms and routines
to normalise and analyse raw gene count matrixes to extract
biological signals. To decrease technical bias due to different
sequencing depth, 24 million reads were randomly selected
for each sample using a draw without replacement. Abun-
dance of each gene in a sample was normalised by dividing
the number of reads that uniquely mapped to a gene by its
nucleotide length. Then, normalised gene abundance was
transformed in to frequencies by dividing with 24 million
(see online Supplementary Fig. S1). The resulting set of
gene frequencies, the microbial gene profile of an individual,
was used for further analyses.
Microbial gene richness was measured by counting the
number of genes that are present for a given sample using a
downsized count matrix as performed in the original
studies(4,5). To be able to compare the present study and the
former ones, we used the same method, estimating gene
count richness using at 11 million unique reads matrix and a
gene richness categorical variable computed by applying a
threshold of 480 000 bacterial genes, to distinguish low from
high gene count(4,5). A prediction model for bacterial richness
based on the six bacterial species was applied in a receiver
operating characteristic analysis as described previously(5),
computing the sum of mean abundance of species with
greater abundance in high gene count than in low gene
count minus the sum of those with greater abundance in
low gene count than in high gene count. Richness was esti-
mated using either shared or unique matrix downsized
matrices, and either gene count for richness or richness
index such as exponential of Shannon richness index or
inverse Simpson index.
Differentially abundant genes between both time points
were selected for each diet using paired Wilcoxon test
(P,0·01), then clustered into metagenomic species (MGS),
using the method based on binning co-abundant genes
across all individuals samples reported previously(5).
To verify that the genes from a given cluster belonged to
the same genome and to annotate the MGS taxonomically,
we performed blastN and blastP analyses using a collection
of 6006 genomes (the available reference genomes from the
National Center for Biotechnology Information and the set
of draft gastrointestinal genomes from the Data Analysis and
Coordination Center of the HMP and MetaHIT (3 August
2012 version)). MGS were assigned to a given genome when
more than 80 % of the genes matched the same genome
using blastN, at a threshold of 95 % identity over 90 % of
gene length. The remaining MGS were annotated using
blastP analysis and assigned to a given taxonomical level
from genus to super kingdom level if more than 80 % of
their genes had the same level of assignment. Data were
indexed in a relational database permitting downstream
access to genes, gene function, phylogeny and covariation
analysis.
Quantification of SCFA using the ethyl
chloroformate-NEFA method
For the quantification of SCFA, approximately 10 g of stool
were mixed with an equal amount of deionised H2O
(18·2 MV) filtered water (0·22 mm). Sample preparation, ana-
lyses by the ethyl chloroformate NEFA method and GC,
were performed by applying methods described in detail by
Amer et al.(30). Quantification of ethyl chloroformate-NEFA
esters was obtained using external calibration curves for
each NEFA. The two isotopic standards butyric internal stan-
dard (D7, 98 %) and Cambridge Isotope Laboratories, Inc.
were used as internal standard for butyric acid.
Statistical analyses
Effect of dietary interventions on biochemical and anthropo-
metric parameters was analysed for completers by multiple
linear regression models adjusted for baseline values, with
stepwise backward elimination of the following covariates:
age; body fat percentage (baseline); energy intake in the
week preceding the last visit; changes in weight and physical
activity level during the intervention. Log-transformation was
applied to non-normally distributed variables. Comparisons
of two means were performed using t tests. Regression coeffi-
cients, CI and P-values are reported from the adjusted
regression models, while non-adjusted mean values for
changes in biochemical parameters during the intervention
are reported in Table 2. Correlation analyses between bacterial
gene count and biochemical measures were analysed by
Spearman’s rank correlation coefficient. At an explorative
level, the potential effect of diet-induced compositional
changes in the gut microbiota on metabolic markers was
examined by separate analyses where MGS that changed
during the intervention were included as explanatory
variables in the multiple regression models. Statistical signifi-
cance was considered at a threshold value of 0·05. Analyses
were performed using MetaOMinerR package (developed
at Metagenopolis, INRA) and JMP version 9.0.2 (SAS
Institute, Inc.).
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Results
A total of fifty-three participants completed the study (91 %).
Dropout rates were not significantly different between
groups, and no significant differences were found between
dropouts and completers in anthropometric and biochemical
characteristics at baseline. Details on recruitment, rando-
misation and study flow are shown in Fig. 2. Baseline
characteristics for all the participants by intervention group
are presented in Table 1. There were no differences in the
anthropometric measures between groups; however, the
participants in the L. paracasei F19 group had significantly
impaired insulin sensitivity compared with the flaxseed
mucilage group, and a significantly lower bacterial gene
count compared with the placebo group. All the participants
reported to have consumed at least 75 % of the study products
during the 6 weeks of intervention, and the mean compliance
score was above 90 % in all the groups.
Diet-induced changes in biochemical markers
Multiple linear regression analyses of the effect of dietary
intervention on biochemical markers showed that the intake
of flaxseed mucilage over 6 weeks improved insulin sensitivity
as shown by a decrease in the serum C-peptide and insulin
response following the OGTT. The AUC values for serum
C-peptide and insulin were 337 pmol/l per min (95 % CI
168·7, 505·1) and 65·9 pmol/l per min (95 % CI 26·5, 105·2)
lower compared with placebo (adjusted values), correspond-
ing to 12 and 13 % improvement within the flaxseed mucilage
group (Table 2). Matsuda’s index was increased by 0·4 (95 %
CI 0·1, 0·7), compared with placebo (adjusted values); corre-
sponding to 11 % increase within the flaxseed mucilage
group. Markers for lipid metabolism and inflammation were
reduced after 6 weeks in the flaxseed group (Table 2); how-
ever, there were no significant differences compared with
placebo. There was no effect of L. paracasei F19 on insulin
sensitivity, lipid metabolism, inflammatory markers or anthro-
pometric measures compared with placebo (Table 2).
Diet-induced changes in gut microbiota composition
Sequenced reads mapped against the MetaHIT gene catalogue
of 3·3 million genes at a normal range of 61 (SE 6) %. Of the
fifty-three participants, forty-nine (92·5 %) had high gene
count and four (7·5 %) had low gene count; two in the
group allocated to L. paracasei F19 and two in the group allo-
cated to flaxseed mucilage. A prediction model for bacterial
richness based on six bacterial species, introduced by Cotillard
et al.(4), was applied to the current data set and an AUC value
of 0·94 was obtained.
At baseline, total bacterial gene count, which is a measure
of gut bacterial richness, correlated negatively with total
cholesterol (r 20·28, P¼0·043), LDL-cholesterol (r 20·30,
Seventy individuals assessed for eligibility
Fifty-eight randomised
Nineteen randomised to receive L. paracasei F19 Nineteen randomised to receive flaxseed mucilage
Nineteen received allocated intervention Nineteen recevied allocated intervention
Twenty randomised to receive placebo
Twelve excluded
Five did not meet inclusion criteria
Seven discontinued for other reasons
(lack of time, family problems or
inability to comply with the protocol)
Twenty recevied allocated intervention
0 lost to follow-up
One discontinued L. paracasei F19
(inability to comply with the diet)
Eighteen included in the analyses Nineteen included in the analyses Sixteen included in the analyses
0 discontinued flaxseed mucilage Four discontinued placebo (One due to
lack of time, One due to inability to
comply with the diet, Two excluded
due to antibiotic treatment)
0 lost to follow-up 0 lost to follow-up
Fig. 2. Flow chart of the study.
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P¼0·029), leucocytes count (r 20·34, P¼0·015) and aspartate
aminotransferase (r 20·33, P¼0·018), and tended to correlate
negatively with AUC glucose (r 20·25, P¼0·069) and alanine
aminotransferase (r 20·24, P¼0·091).
Within the flaxseed mucilage group, bacterial gene count
decreased with 47 271 genes over 6 weeks (95 % CI
282 176, 212 366, P¼0·011); however, this change was not
significantly compared with placebo (P¼0·144). Bacterial
gene count did not change within the L. paracasei F19
group (P¼0·473). The gene loss following intake of flaxseed
mucilage for 6 weeks was confirmed by measures of a diver-
sity; when evaluated by the exponential of Shannon diversity
index and Simpson’s inverse index, the decrease in diversity
was 38 010 (95 % CI 264 473, 211 546, P¼0·007) and 17 515
(95 % CI 230 992, 24038, P¼0·014), respectively.
Comparison of microbiota composition at baseline and
after 6 weeks of intervention with L. paracasei F19 showed
alterations in faecal abundance of 2493 bacterial genes assigned
to two MGS that increased during the intervention relative
to baseline. These were identified as the species Eubacterium
rectale and Ruminococcus torques. The proportion of total
distributions of E. rectale recovered after analysis increased
3·3 times (P¼0·003) and R. torques increased 4·5 times
(P,0·001).
The placebo intervention led to altered faecal abundance of
7436 genes assigned to six MGS (P,0·01), where the relative
abundance of four MGS (Roseburia hominis, two Clostridiales
and one unknown) decreased and the relative abundance of
two MGS (Eubacterium ventriosum and one unknown)
increased.
Comparison of microbiota composition at baseline and after
6 weeks of intervention with flaxseed mucilage showed altera-
tions in faecal abundance of 41 090 bacterial genes assigned to
thirty-three MGS, the relative abundance of twenty-four MGS
decreased and nine MGS increased (Table 3 and Fig. 3). Of
the thirty-three MGS that changed, twenty-four were identified
at phylum level or below. Eight of the MGS identified as
decreasing during the intervention were assigned to the Fae-
calibacterium genus, among which three F. prausnitzii
species with sequence homology to the strains F. prausnitzii
Table 1. Baseline characteristics presented by diet group
(Mean values and standard deviations)
Lactobacillus paracasei
F19 (n 19) Flaxseed mucilage (n 19) Placebo (n 20)
Mean SD Mean SD Mean SD
Age (years) 61·4 6·5 60·6 6·4 58·5 5·3
Height (cm) 163 5·8 164 7·0 165 5·7
Weight (kg) 91·1 9·4 93·8 7·8 93·8 11·5
BMI (kg/m2) 34·2 3·1 35·2 4·5 34·3 3·8
Waist circumference (cm) 105 6·8 104 9·2 104 11·0
IAAT (cm2) 172 21·2 171 28·6 169 33·4
Body fat (%) 46·7 4·1 48·0 3·3 46·8 3·6
Energy intake (kJ/d) 7824 1962 6859 1922 8153 1121
Protein (E%) 18·4 3·0 19·4 4·9 19·2 2·6
Carbohydrates (E%) 41·5 5·6 39·7 8·6 41·6 6·0
Fat (E%) 34·7 6·5 35·2 6·9 36·4 5·9
24-h-MET-time 41·6 9·3 38·4 8·8 41·7 8·1
Fasting plasma glucose (mmol/l) 5·89 0·76 5·75 0·90 5·81 0·77
Fasting serum insulin (pmol/l) 113 55 71 32 89 56
Fasting serum C-peptide (pmol/l) 958 344 713 185 816 385
AUC glucose (mmol/l per min) 7·6 1·7 7·0 1·7 6·8 1·0
AUC insulin (pmol/l per min) 476 212 331 154 420 303
AUC C-peptide (pmol/l per min) 3056 966 2466 754 2714 1204
HOMA-IR 5·11 2·91 3·16 1·76 3·94 2·59
Matsuda index 1·79 1·02 2·82 1·65 2·65 1·89
Serum total cholesterol (mmol/l) 6·13 1·06 6·36 0·89 5·76 0·69
Serum HDL-cholesterol (mmol/l) 1·46 0·26 1·40 0·22 1·56 0·42
Serum LDL-cholesterol (mmol/l) 3·73 0·84 4·11 0·84 3·44 0·74
Serum TAG (mmol/l) 1·69 0·83 1·51 0·77 1·07 0·32
Plasma ANGPTL4 (ng/ml) 8·16 3·08 7·77 3·06 7·59 1·36
Leucocyte count (109/l) 5·55 1·05 5·46 0·92 5·60 1·64
Plasma hsCRP (mg/l) 2·90 3·78 3·73 3·69 4·14 2·90
Serum TNF-a (pg/ml) 2·66 3·53 2·64 1·60 1·81 0·70
Plasma IL-6 (pg/ml) 1·40 0·43 2·69 3·54 1·82 0·92
Plasma LBP (mg/l) 18·7 5·9 19·6 7·2 18·5 7·6
Total faecal SCFA (mg/kg)* 1901 1067 1556 1006 1692 869
Faecal butyric acid (mg/kg)* 917 632 892 508 907 443
Bacterial gene count* 556 338 144 657 618 100 114 608 646 688 77 872
Exponential Shannon index* 139 343 59 749 176 741 59 046 179 518 53 269
Inverse Simpson index* 44 335 25 089 55 039 24 854 55 654 23 140
IAAT, intra-abdominal adipose tissue; E%, energy percentage; 24-h-MET-time, 24-h metabolic equivalent value; HOMA-IR, homeostatic model assessment of insulin resist-
ance; ANGPTL4, angiopoietin-like protein 4; hsCRP, high-sensitivity C-reactive protein; LBP, lipopolysaccharide-binding protein.
* The analyses are only performed in fifty-three completers.
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A2-165, F. prausnitzii SL3/3 and F. cf. prausnitzii KLE1255.
The proportion of total distributions of these three species
decreased 0·6 times (P,0·01). Moreover, Ruminococcus
lactaris decreased 0·9 times during the flaxseed mucilage
intervention (P¼0·005).
Three of the nine MGS that increased in relative abundance
after the flaxseed mucilage intervention were assigned to the
Clostridium genus (Table 3 and Fig. 3). Furthermore, three
MGS were identified to species level as Bilophila
wadsworthia, Parabacteroides merdae and Parabacteroides
johnsonii. The proportion of total distributions of these
three species increased 2·6 times (P,0·001), 3·6 times
(P¼0·004) and 4·7 times (P,0·001), respectively.
Effect of gut microbiota on the improvement
in insulin sensitivity
When exploring the role of relative changes in the gut micro-
biota on improvement in insulin sensitivity in the flaxseed
mucilage group, the MGS that changed during the intervention
were included in the multiple regression models in separate
analyses. Relative changes in the MGS did not contribute to
the effect of the flaxseed mucilage intervention on Matsuda
index or AUC values for insulin and C-peptide, when separate
analyses were performed where the delta values for the
individual MGS were included in the model as explanatory
variables.
Table 2. Biochemical characteristics after 6 weeks of dietary intervention and changes from baseline
(Mean values with their standard errors)
Lactobacillus
paracasei F19 (n 18)
Flaxseed mucilage
(n 19) Placebo (n 16)
Mean SE Mean SE Mean SE P*
Fasting plasma glucose (mmol/l) 5·75 0·17 5·67 0·16 5·58 0·14
D Glucose 20·16 0·083 20·083 0·082 20·30 0·14 0·524
Fasting serum insulin (pmol/l) 114 13 72 8·0 104 12
D Insulin 20·65 5·75 0·52 4·69 9·05 6·76 0·166
Fasting serum C-peptide (pmol/l) 970 91 699 51 917 83
D C-peptide 4·9 37·0 213·7 33·3 57·7 53·3 0·258
AUC glucose (mmol/l per min) 7·49 0·43 6·91 0·38 7·00 0·29
D AUC glucose 20·035 0·17 20·20 0·15 0·091 0·16 0·523
AUC insulin (pmol/l per min) 504 52 297 32 481 71
D AUC insulin 27 29 244 19 39 27 0·001
AUC C-peptide (pmol/l per min) 3175 252 2204 132 2866 283
D AUC C-peptide 110 127 2297 93 101 116 0·001
HOMA-IR 5·07 0·70 3·06 0·36 4·00 0·65
D HOMA-IR 20·12 0·07 20·10 0·051 20·25 0·11 0·296
Matsuda index 1·81 0·24 3·05 0·40 2·17 0·36
D Matsuda index 0·022 0·12 0·25 0·21 20·35 0·31 0·048
Serum total cholesterol (mmol/l) 6·24 0·28 5·89 0·21 5·72 0·17
D Total cholesterol 0·12 0·18 20·47 0·13 20·11 0·13 0·154
Serum HDL-cholesterol (mmol/l) 1·45 0·056 1·34 0·047 1·54 0·089
D HDL-cholesterol 20·0067 0·036 20·058 0·040 0·013 0·041 0·150
Serum LDL-cholesterol (mmol/l) 3·81 0·23 3·72 0·20 3·46 0·17
D LDL-cholesterol 0·085 0·15 20·39 0·10 20·089 0·11 0·068†
Serum TAG (mmol/l) 1·96 0·22 1·48 0·12 1·16 0·079
D TAG 0·24 0·14 20·028 0·14 0·13 0·057 0·205
Plasma ANGPTL4 (ng/ml) 7·80 0·67 6·92 0·60 7·19 0·47
D ANGPTL4 20·25 0·33 20·85 0·46 20·69 0·52 0·142
Leucocyte count (109/l). 5·41 0·25 5·14 0·26 5·50 0·34
D Leucocyte count 20·18 0·17 20·33 0·22 0·07 0·15 0·290
Plasma hsCRP (mg/l) 3·43 0·95 2·68 0·80 2·89 0·66
D hsCRP 0·43 0·26 20·91 0·20 21·25 0·45 0·036†
Serum TNF-a 2·79 0·78 2·60 0·43 1·63 0·14
D TNF-a 0·056 0·13 20·043 0·15 20·011 0·16 0·419
Plasma IL-6 1·54 0·12 2·10 0·36 1·73 0·25
D IL-6 0·10 0·091 20·59 0·49 20·16 0·16 0·644
Plasma LBP (mg/l) 19·7 1·5 18·1 1·5 16·3 1·5
D LBP 0·56 0·82 21·51 0·84 21·88 0·93 0·221
Total faecal SCFA (mg/kg) 1730 224 1477 190 1685 231
D SCFA 2171 242 279 239 26·9 145 0·890
Faecal butyric acid (mg/kg) 789 128 806 93 837 89
D Butyric acid 2128 148 286 157 270 94 0·811
D, change during the 6 weeks of dietary intervention (unadjusted values); HOMA-IR, homeostatic model assessment of insulin resistance; ANGPTL4, angio-
poietin-like protein 4; hsCRP, high-sensitivity C-reactive protein; LBP, lipopolysaccharide-binding protein.
*P-values are reported from linear regression models of the effect of dietary group on the specified parameters, when adjusted for relevant covariates includ-
ing baseline values.
† The difference is to be found between the F19 and flaxseed mucilage group, but not when these are compared with placebo by Student’s t test.
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Adverse events
During the initial 4 weeks of the intervention, more adverse
events were reported in the flaxseed group (n 11), compared
with the placebo group (n 4; P¼0·023), while there was no
difference in the occurrence of adverse events between the
placebo and the L. paracasei F19 group (n 8; P¼0·297). The
adverse events reported following the flaxseed intervention
were increased flatulence and changed bowel habits with
more frequent defecation and looser stool consistency. After
6 weeks, these symptoms were diminishing and only reported
in seven participants, which was not different from the
placebo group. There was no difference between the adverse
events reported following the probiotic and placebo inter-
vention that included both more frequent and less-frequent
defecation. No serious adverse events were registered during
the study.
Discussion
The present study shows that daily intake of flaxseed mucilage
over 6 weeks can improve insulin sensitivity and modify the
gut microbiota in individuals with obesity. The relative
decrease in the abundance of F. prausnitzii species following
intake of flaxseed mucilage is surprising given the improve-
ment in insulin sensitivity. Previous metagenomic studies
have suggested that F. prausnitzii is more abundant in healthy
individuals than in individuals with T2D(3,7). In addition, pre-
biotics have been shown to induce a parallel increase in the
faecal abundance of F. prausnitzii and improvement in insulin
sensitivity in individuals with obesity(11). A beneficial effect of
F. prausnitzii on insulin sensitivity has been hypothesised to
be due to its role as a major producer of the SCFA butyrate(31),
as butyrate seems to have an anti-inflammatory potential that
might improve obesity-related metabolic complications such
as insulin resistance(32). The relative lower abundance of F.
prausnitzii following intake of flaxseed mucilage is supported
by the reduction observed in faecal butyrate content and
by results from a previous study performed in rats, where
fermentation of flaxseed fibres had been shown to yield a
remarkably low proportion of butyrate, when compared
with other dietary fibres(22).
The improvement in insulin sensitivity following intake of
flaxseed mucilage was accompanied by reductions in markers
for inflammation and dyslipidaemia, although these changes
were non-significant, compared with the placebo group. The
gut microbiota has been implicated in the low-grade inflam-
mation that characterises the progression from obesity to
metabolic disease, as translocation of bacterial toxins, such
as lipopolysaccharides, into the circulation can activate inflam-
matory pathways(33,34). Impaired gut barrier function can be
caused by adipocyte-derived inflammatory cytokines(35), and
increased translocation of lipopolysaccharides can be induced
by a high-fat diet(36,37). Thus, it is likely that the gut is an
important mediator in obesity-related systemic inflammation.
Prebiotic-induced modulation of the gut microbiota has
been proposed to inhibit translocation of lipopolysaccharides
based on observations in mice(38); however, it is still unclear to
what degree such mechanisms apply to human subjects. Since
the decrease in LBP, hsCRP, TNF-a and IL-6 in the present
study did not differ between the flaxseed mucilage and the
placebo group, the improvement in insulin sensitivity did
not appear to be mediated through inhibition of lipo-
polysaccharide translocation.
The design of the present study allowed us to explore
whether the improvement in insulin sensitivity following
intake of flaxseed mucilage could be due to a gut microbiota
modulating effect. However, analyses showed that the
changes in relative abundance of bacterial species induced
by flaxseed mucilage did not explain any of the changes in
the biochemical markers. When this is considered in relation
to the flaxseed mucilage-induced changes in the microbiota
that, based on the existing literature, are not in line with an
improved host metabolic phenotype, we conclude that
changes in the gut microbiota following intake of flaxseed
mucilage do not appear to be a contributing factor to the
beneficial effect of flaxseed mucilage on insulin sensitivity.
Previously, it has been shown that daily intake of 5 g flaxseed
mucilage reduced fasting blood glucose, total cholesterol and
LDL-cholesterol in patients with T2D after 12 weeks(20), and
reduced total- and LDL-cholesterol in healthy individuals
after 1 week(21). In addition, acute meal tests with flaxseed
mucilage have been shown to suppress postprandial blood
glucose, insulin and lipid responses(19,39). The beneficial meta-
bolic effects of flaxseed mucilage observed in these previous
studies and in the present study would then appear to be
due to the ability of the soluble viscous fibres to delay gastric
emptying and inhibit nutrient absorption rather than their abil-
ity to induce specific changes in the gut microbiota. Although,
it cannot be excluded that the effect on insulin sensitivity was
mediated through undetected bacterial species or changes in
proteins and metabolites present in the gut that were not
measured in the present study. The dominating molecular
pathways in the bacterial species that increased during the
flaxseed mucilage intervention are involved in pro-inflam-
matory signalling and managing of oxidative stress, pathways
that have previously been suggested to be enriched in
Table 3. Gut bacteria changes in relative abundance after 6 weeks of
intervention with 10 g flaxseed mucilage
Taxonomic level n Annotation
Decreased relative abundance
Species 1 Ruminococcus lactaris
Species 3 Faecalibacterium prausnitzii
Genus 5 Faecalibacterium
Genus 1 Ruminococcus
Genus 1 Eubacterium
Family 1 Erysipelotrichaceae
Family 2 Lachnospiraceae
Order 3 Clostridiales
Phylum 1 Firmicutes
6 Unknown
Increased relative abundance
Species 1 Bilophila wadsworthia
Species 1 Parabacteroides merdae
Species 1 Parabacteroides johnsonii
Genus 3 Clostridium
3 Unknown
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individuals with obesity-related metabolic diseases(5). This
shift towards a gut microbiome with a more pro-inflammatory
potential might be explained by the fact that the flaxseed
mucilage intervention provided more Cd in the diet. Despite
that the Cd content in the flaxseed mucilage was at a
concentration considered harmless to human health
(0·113 mg/kg)(40), it still might have induced modifications in
the gut microbiome. This has been observed in previous
studies in mice, where alterations were induced in the
gut microbiome following administration of environmental
relevant low doses of Cd in drinking-water over 3–8
weeks(41–43).
This study showed a very limited effect of L. paracasei F19
(9·4 £ 1010 colony-forming units/dose) on the gut microbiota
and metabolic markers, which were non-significant compared
with the placebo group. The storage of L. paracasei F19 was
Ruminococcus lactaris (2561)
Faecalibacterium prausnitzii A2 –165 (2520)
Faecalibacterium prausnitzii SL3/3 (2862)
Faecalibacterium cf. prausnitzii KLE1255 (2268)
Faecalibacterium (1644)
Faecalibacterium (2367)
Faecalibacterium (2011)
Faecalibacterium (1816)
Faecalibacterium (1879)
Ruminococcus (2111)
Eubacterium (3020)
Erysipelotrichaceae (2403)
Lachnospiraceae (2256)
Lachnospiraceae (2160)
Clostridiales (1328)
Clostridiales (3228)
Clostridiales (1494)
Firmicutes (1500)
unk. (1965)
unk. (2262)
unk. (2245)
Gene abundance
colour code
Low
Week 6
enriched
Week 0
enriched
High
unk. (3925)
unk. (2190)
unk. (2721)
Bilophila wadsworthia (6098)
Parabacteroides merdae (3824)
Parabacteroides johnsonii (2687)
Clostridium (2555)
Clostridium (2893)
Clostridium (2616)
unk. (4332)
unk. (2269)
unk. (1637) 3·2×10–3
1·7×10–2
3·5×10–4
3·1×10–3
3·5×10–4
3·0×10–4
7·1×10–3
1·0×10–2
4·1×10–3
1·7×10–2
9·2×10–3
7·4×10–3
9·2×10–3
9·6×10–3
1·2×10–2
1·2×10–2
9·2×10–3
2·2×10–3
4·1×10–3
1·7×10–2
4·1×10–3
7·1×10–3
1·7×10–2
4·1×10–3
2·0×10–3
7·1×10–4
7·4×10–3
4·1×10–3
7·1×10–3
4·1×10–3
4·1×10–3
3·4×10–3
7·4×10–3
fdrWeek 6Week 0
Fig. 3. The presence and abundance of the thirty-three species that differed significantly before and after 6 weeks of intervention with flaxseed mucilage. Each
barcode illustrates the abundance of a species, either enriched at baseline (top) or week 6 (bottom): samples are in columns (same order for both time points)
and the fifty ‘tracer’ genes are in rows. Gene abundance is indicated by colour gradient from white (not detected) over blue, green and yellow to red (most abun-
dant). Taxonomical information is given for each species; the number of genes within each metagenomic species is given in parenthesis. Fdr, Benjamini Hochberg
multiple testing correction of paired Wilcoxon tests; unk., unknown taxonomy.
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optimised to ensure that the probiotic strain was alive at inges-
tion. The diary kept by the participants indicated that they
were highly compliant to the intervention.
A combined effect of this probiotic strain on both metage-
nomic and metabolic markers in human subjects has not
been explored previously. In mice, L. paracasei F19 has
been shown to affect the immune system and expression of
genes involved in energy homeostasis and insulin sensi-
tivity(44), and to regulate body fat storage and lipoprotein
metabolism(45). Observational studies in human subjects
have suggested that L. paracasei is associated with normal
weight(15) and negatively correlated with fasting blood glu-
cose(16) despite that several other Lactobacillus species have
been suggested to be associated with obesity(16,46,47) and
T2D(7). It is possible that we would have observed an effect
of the probiotic intervention if it had been administered as
part of a fermentable milk product, as a fermentable food
matrix could potentially enhance probiotic efficacy(48). A
study among elderly has shown that daily intake of a fermen-
ted milk product with L. paracasei F19 (5·25 £ 108 colony-
forming units) over 4 weeks stimulates the growth of other
Lactobacillus species in the gut(49). However, no effect on
other Lactobacillus species was observed following 6 weeks
of intake of L. paracasei F19 in the present study, although
it cannot be excluded that the abundance of Lactobacillus
species not included in the gene catalogue did change(29).
The inclusion criteria in the present study were designed in
order to recruit individuals at increased risk of metabolic
diseases. Previous metagenomic studies have suggested that
individuals with a metabolic risk profile are characterised by
low gut microbiome richness(4,5). The obese participants in
these previous studies were comparable to the participants
in the present study from a phenotype perspective; thus, it
is surprising that only 8 % of the individuals in the present
study had low gut microbiome richness as opposed to
23–40 % in the other cohorts(4,5). The protocol for handling
and analyses of microbiota samples were similar to the
samples handling in the MetaHIT study(5); however, it is
possible that deviations in the prevalence of low microbiome
richness between the cohorts can be explained by differences
in habitual dietary habits. Yet, the negative correlations
identified between bacterial gene count and metabolic risk
markers support an association between gut microbiome
richness and metabolic health. As does the lower microbiome
richness detected at baseline in the participants allocated to
L. paracasei F19, who were characterised by impaired insulin
sensitivity, compared with the two other groups. This is
interesting as the prediction model based on six bacterial
species that has previously been demonstrated as a tool to
identify individuals with low microbiome richness in two
other obese cohorts(4,5) also showed high specificity and sen-
sitivity in this cohort.
In conclusion, the present study shows that intake of
flaxseed mucilage improves insulin sensitivity and changes
the gut microbiota in obese postmenopausal women, but
suggests that the effect on insulin sensitivity is independent
of the flaxseed mucilage-induced changes in abundance of
bacterial species.
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